ArticleScientific reports2025
Inhibition of monkeypox polymerase holoenzyme and methyltransferase using bioactive compounds of black tea: a computational approach.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The WHO declared monkeypox a global health emergency due to its rapid spread. In response, the FDA authorized emergency use of the Jynneos vaccine despite its adverse effects, while smallpox antivirals, repurposed for monkeypox treatment, have shown limited efficacy, highlighting the need for better therapeutics that are biocompatible, less toxic, and more accessible. Tea bioactives, known for their antiviral properties, were evaluated using an in silico approach to target viral enzymes: polymerase holoenzyme and methyltransferase. A total of 68 bioactives, mainly polyphenols from tea, were analyzed through molecular docking. Among them, digalloylprocyanidin B2, TSB, and NTF showed the lowest binding energies of -9.6441 kcal mol
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.